NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
Clinical Trials
28 trialsNCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT05467189 2022-07-20
Antineoplastic Drugs in Elderly Patients
Shandong University
Recruiting
NCT00206427 2021-09-29
GW
Baylor Breast Care Center
Phase 2 Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT00107003 2018-07-05
GW572016 to Treat Recurrent Malignant Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00790816 2018-02-28
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Novartis
Phase 1 Completed
NCT00148902 2017-12-06
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01290354 2017-11-13
Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01013740 2017-05-31
VITAL
Novartis
Phase 2 Completed
NCT01332396 2017-04-26
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
Novartis
Completed
NCT01328054 2016-06-08
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
GlaxoSmithKline
Phase 4 Completed
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT00632489 2015-06-08
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00975988 2014-10-27
Regulatory TYKERB® Tablets PMS
GlaxoSmithKline
Completed
NCT01077648 2014-05-26
Brain Metastasis in Breast Cancer Patients
GlaxoSmithKline
Completed
NCT00486954 2013-06-20
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
GlaxoSmithKline
Phase 3 Completed
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT01128543 2012-12-12
Lapatinib in Combination With Vinorelbine
GlaxoSmithKline
Phase 2 Completed
NCT00447226 2012-06-12
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
GlaxoSmithKline
Phase 2 Terminated
NCT00888810 2009-04-28
TOPO-LAPA
Centre Francois Baclesse
Phase 2 Terminated